Dr. Robert Daber is a board-certified geneticist with expertise in Genomics and Bio-Informatics and has spent much of his career building clinical Next Generation sequencing programs. He holds a PhD in Biochemistry and Molecular Biophysics from the University of Pennsylvania School of Medicine and received his clinical genomic training while a Fellow at the Children’s Hospital of Philadelphia. After completing his fellowship, he assembled a team that built and launched the Center for Personalized Diagnostics (CPD), a new Clinical Genomics laboratory focused on oncology Next Generation Sequencing at the University of Pennsylvania. During his tenure at the CPD, Bob was responsible for developing new assays and Informatic algorithms, deploying custom software tools to manage lab workflow (LIMS) and data review as well as case review and sign-out for a variety of tumor cases. After overseeing the laboratory for several years Bob moved on to build the tumor sequencing laboratory at BioReference. While building this program he also oversaw all NGS technical operations, created new Bio-informatics and Research and Development departments and eventually was placed in charge of NGS operations and R&D for both BioReference and its subsidiary GeneDx. During his career Bob has played an instrumental role developing broad genomic partnerships with health systems and has established a national reputation as an authority of all aspects of genomic operations including bioinformatics, operations, technology, regulatory affairs and best practices.
Harpreet brings ten years of experience in genomics space to our team. She comes with a strong scientific background and experience in precision medicine, genomics, laboratory testing, pricing and reimbursement models for molecular diagnostics. Most recently, she worked as Senior Director of Marketing at Babygenes, a genetic testing company focused in Newborn Diagnostics arena. Prior to that, she led cross-functional teams at GeneDx to achieve successful launches of genetic tests for various medical specialties, and development of go-to-market strategies in highly competitive markets.
She not only led the GeneDx marketing department since 2008, but was also instrumental in setting-up the GeneDx billing operations and managing them from 2013 to 2015. She earned her MBA from NYU Stern School of Business and Masters in Biotechnology from University of Pennsylvania.
Dr. Michael Moreau is a molecular geneticist with extensive expertise in assay development, biotechnology, and laboratory automation. He holds a PhD in Microbiology and Molecular Genetics from Rutgers University, with specialized training in human psychiatric genetics. His doctoral thesis in the laboratory of Dr. Linda Brzustowicz investigated the role of microRNAs and other noncoding RNAs in the etiology of Schizophrenia. After completing his PhD, Dr. Moreau worked as a laboratory researcher and then as Associate Director of Analytical and Informatics Services at RUCDR Infinite Biologics. He provided broad technical and logistical oversight of projects involving microarray and Next Generation Sequencing (NGS) technologies. In his time at RUCDR, Dr. Moreau expanded his expertise in biobanking operations, which includes automated, high-throughput sample management and analysis. After leaving RUCDR, Dr. Moreau worked as technical supervisor and Assistant Director of Genomics at BioReference Laboratories. He served an instrumental role in validating and launching NGS-based tests, automating, streamlining and scaling up operations across multiple departments.
Dr. Falshruti Patel received her Ph.D. in Cell and Developmental Biology from the University of Medicine and Dentistry of New Jersey (UMDNJ), while representing the graduate candidates and serving as an officer of the New Brunswick chapter.
Post-graduation, she joined the Clinical Genomics group at RUCDR where she established a licensed and accredited genomic testing facility with a focus on next generation sequencing and micro-arrays. At RUCDR, Falshruti oversaw technical operations, quality and regulatory compliance of the diagnostic facility for local hospitals and its affiliates, pharmaceutical companies and National Institutes. She managed cross-functional teams for design and launch of assays and efficient workflows with a goal to power precision medicine through research, clinical trials and diagnosis in a competitive environment of healthcare genomics.
Simultaneously, she complemented her scientific career with a Masters of Business Administration degree from Rutgers Business School where she focused on global strategy and leadership. She has combined her passion for science and business in the rapidly evolving Genomics industry.
Adrian is a scientist with extensive expertise in Next-Generation Sequencing (NGS) and laboratory operations. He holds an M.S. in Biology from the University of Louisiana Monroe where he specialized in behavioral ecology, studying the evolution of social behavior in degus. The use of molecular tools in his master’s research led him to an interest in genomics and he applied this skillset as a laboratory researcher and then as NGS Operations Manager at RUCDR Infinite Biologics. In his time at RUCDR, Adrian coordinated high-throughput sequencing projects with clients and supervised a team of technicians to manage NGS projects from design to completion. After leaving RUCDR, Adrian worked as Clinical Genomics Supervisor at Bioreference Laboratories, supervising a team of technologists and managing a variety of clinical NGS assays in the departments of cancer cytogenomics and reproductive genomics. Adrian then worked as Senior Clinical Sequencing Specialist at CooperGenomics, optimizing and implementing a clinical NGS carrier-screening assay and training technicians to carry out multiple other clinical assays.